Evidence map›Paper›PMID 41184994›Full record

ArticleBMC pulmonary medicine2025

Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study.

Yuhui Qiang, Hongyi Wang, Yifei Ni, Jianping Wang, Anqi Liu, Jie Du, Linfeng Xi, Yinan Hu, Yanhong Ren, Bingbing Xie and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuhui Qiang *Immune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Hongyi Wang *National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, No. 2 Yinghua Dong Street, Chao Yang District, Beijing, 100029, P.R. China.
Yifei NiChina-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jianping WangImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Anqi LiuChina-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jie DuChina-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Linfeng XiImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Yinan HuImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Yanhong RenImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Bingbing XieImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Shiyao WangImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Jing GengImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China.
Min LiuDepartment of Radiology, China-Japan Friendship Hospital, No. 2 Yinghua Dong Street, Chao Yang District, Beijing, 100029, China. mikie0763@126.com.
Huaping DaiImmune Dysfunction and Pulmonary Fibrosis Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, P.R. China. daihuaping@ccmu.edu.cn.

Funding

National Key Technologies R & D Program Precision Medicine Research 2021YFC2500700 and 2016YFC0901101National Natural Science Foundation of China 81870056
6 · The paper itself

Abstract

backgroundThis study aimed to investigate longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) on high-resolution computed tomography (HRCT).

methodsThis prospective cohort study was undertaken involving 514 IIM-ILD patients (367 females; median age 54 years) from 2016 to 2022. Deep learning algorithms were employed to quantify interstitial lesions on HRCT, while clinical parameters including pulmonary function tests, serum biomarkers, and arterial blood gas analysis were also considered.

resultsThe study identified anti-MDA5 antibody positivity (OR: 10.46, 95% CI: 3.40-32.22), reduced FVC (OR: 0.91, 95% CI: 0.84-0.98), and extensive ground-glass opacity (GGO) (OR: 1.07, 95% CI: 1.01-1.13)/ reticulation (OR: 1.23, 95% CI: 1.07-1.41) involvement as independent risk factors for rapidly progressive interstitial lung disease (RP-ILD) within IIM. During the rapid progressive period of RP-ILD, anti-MDA5-positive dermatomyositis (MDA5 + DM) showed greater progression in fibrotic, inflammatory, and emphysema lesions compared to anti-synthetase syndrome (ASS). In the slow progressive period, MDA5 + DM tended towards chronic fibrosis, while ASS exhibited overall improvement. The extent of lesion increase in non-RP-ILD patients is significantly smaller than in those who have experienced RP. Reticular and consolidation changes were strongly correlated with variations in VC%, FVC%, and FEV

conclusionsIIM-ILD cases with prior rapid progression will develop chronic fibrotic trajectories with persistent inflammation compared to non-progressive cases. ASS is characterized by sustained inflammatory activity in imaging manifestations, whereas MDA5 + DM shows post-acute fibrotic remodeling following initial injury. Longitudinal GGO emerges as a critical prognostic indicator, demonstrating time-dependent cumulative risk effects.

Indexed as

Lung Diseases, InterstitialMyositisTomography, X-Ray ComputedAdultAgedAutoantibodiesBiomarkersDisease ProgressionFemaleHumansInterferon-Induced Helicase, IFIH1Longitudinal StudiesLungMaleMiddle AgedProspective StudiesAutoantibodiesBiomarkersIFIH1 protein, humanInterferon-Induced Helicase, IFIH1High-resolution computed tomographyIdiopathic inflammatory myopathyLongitudinal analysisQuantitative CTRapidly progressive interstitial lung disease

Identifiers

PMID41184994
PMCPMC12581610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.